Where does Taysha Gene Therapies, Inc.'s cash flow data come from?

Every line is extracted from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Net income	-$109M-22.1%	-$89.3M—	——	-$166.01M+4.9%
Depreciation and amortization	$1.08M-12.0%	$1.23M-12.0%	$1.4M+14.3%	$1.22M+132%
Stock-based compensation	$13.3M+1.5%	$13.1M+65.8%	$7.91M-56.2%	$18.04M-0.8%
Change in accounts payable	-$153K+94.8%	-$2.92M-27.2%	-$2.3M+70.6%	-$7.8M—
Change in other assets	——	-$207K+96.6%	-$6.01M-164%	-$2.28M—
Other working capital changes	-$296K+61.9%	-$776K-4.7%	-$741K+18.2%	-$906K—
Change in deferred revenue	-$9.77M-17.3%	-$8.33M+46.1%	-$15.45M-146%	$33.56M—
Non-cash operating lease expense	$1.36M+11.7%	$1.22M+3.0%	$1.18M-10.1%	$1.32M—
Net cash from operating activities	-$93.09M-14.6%	-$81.23M-11.2%	-$73.02M—	——
Capital expenditures	$738K+96.3%	$376K—	——	$20.62M+34.7%
Other investing activities	-$134K-1,118%	-$11K—	——	$61K—
Acquired in-process research and development	——	——	$3.5M—	——
Net cash from investing activities	——	-$376K+94.9%	-$7.4M+70.3%	-$24.93M-15.7%
Proceeds from issuance of common stock	$1.22M—	——	——	——
Other financing activities	-$337K—	——	——	-$1.1M-114%
Payment of debt issuance costs	——	——	$399K—	——
Net cash from financing activities	$274.59M+256%	$77.04M-45.2%	$140.64M+169%	$52.2M—
Net increase (decrease) in cash	$196.31M+4,103%	-$4.9M—	——	——
Interest paid	$5.4M+2.2%	$5.28M+6.7%	$4.95M+78.5%	$2.78M—
Depreciation	$1.08M-12.0%	$1.23M-12.0%	$1.4M+14.3%	$1.22M+132%
Increase Decrease In Accrued Expense And Other Liabilities	$6.29M—	——	-$6.28M+32.7%	-$9.32M—
Increase (Decrease) in Prepaid Expense and Other Assets	——	-$207K+96.6%	-$6.01M-164%	-$2.28M—
Non Cash Change In Fair Value Of Term Loan	$832K+239%	-$597K-147%	$1.28M—	——
Operating lease right-of-use asset amortization	$1.36M+11.7%	$1.22M+3.0%	$1.18M-10.1%	$1.32M—
Other Noncash Income (Expense)	-$296K+61.9%	-$776K-4.7%	-$741K+18.2%	-$906K—
Payment for (Proceeds from) Other Investing Activity	-$134K-1,118%	-$11K—	——	$61K—
Payments to Acquire in Process Research and Development	——	——	$3.5M-17.6%	$4.25M—
Payment Of Shelf Registration Costs	——	——	——	$358K-0.6%
Proceeds From Issuance Of Common Stock Pursuant To At The Market Offering Net Of Sales Commissions And Other Offering Costs	$48.44M—	——	——	——
Other, net	-$337K—	——	——	-$1.1M-114%
Proceeds from issuance of common stock relating to employee stock plans	——	——	——	——
Accrued payables for capital expenditures	——	$46K+156%	$18K—	——
Fair Value Adjustment Of Warrants	$1.2M—	——	$34.72M—	——
Increase Decrease In Contract With Customer Liability	-$9.77M-17.3%	-$8.33M+46.1%	-$15.45M-146%	$33.56M—
Proceeds From Issuance Of Warrants	$225K—	——	——	——
Leased assets obtained in exchange for operating lease liabilities	$2.37M—	——	——	——
Issuance of warrants	$1.64M—	——	$74.34M—	——
Free cash flow	-$93.83M-15.0%	-$81.6M-6.1%	-$76.89M—	——
Free cash flow	-$93.83M-15.0%	-$81.6M-6.1%	-$76.89M—	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Taysha Gene Therapies, Inc.'s cash flow data come from?: Every line is extracted from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.